Clinical Outcomes of Parenteral Methylene Blue as Adjunct Therapy in Hospitalized COVID-19 Patients: A Retrospective Cohort Study

Kiran G Piparva; Bhavesh R Kanabar; Anil P Singh

doi:10.55489/njmr.160420261407

Authors

Kiran G Piparva Department of Pharmacology, All India Institute of Medical Sciences, Rajkot, Gujarat, India
Bhavesh R Kanabar Department of Preventive & Social Medicine, P.D.U. Medical College, Rajkot, Gujarat, India https://orcid.org/0000-0001-9716-3479
Anil P Singh Department of Pharmacology, P.D.U. Medical College, Rajkot, Gujarat, India https://orcid.org/0000-0003-4673-9890

DOI:

https://doi.org/10.55489/njmr.160420261407

Keywords:

COVID-19, Methylene blue, Drug Repurposing, Cohort Study, length of stay, Hospital Mortality

Abstract

Background: During the pandemic, methylene blue emerged as a repurposed drug for the treatment of COVID-19. The objective was to evaluate clinical outcomes of parenteral methylene blue use in hospitalized COVID-19 patients.

Methodology: A retrospective cohort study was conducted at COVID-19 hospitals in Rajkot, during 2022-2023. “Exposed” cohort (who received standard care plus parenteral methylene blue), “Unexposed” cohort (with standard care) were matched for age, gender, and HRCT scores. Primary outcomes included length of hospital stay and recovery rate. Secondary outcomes assessed changes in serial laboratory parameters. Data were analyzed using appropriate statistical tests using Jamovi Version 2.6.45.

Results: A total of 19 exposed and 34 unexposed patients were analyzed. The exposed cohort had significantly longer hospital stays (median 9 vs. 5 days; p<0.01) and higher mortality (21.1% vs. 2.9%; p=0.09). Baseline hemoglobin (11.30 vs 13.80 g/dL at baseline, p=0.017) was significantly lower in the exposed cohort and showed an initial rise followed by a decline, unlike the stable trend in the unexposed group. D-dimer levels (430.00 vs 220.00 ng/mL at baseline, p=0.02) remained significantly higher in exposed cohort. CRP declined similarly whereas IL-6, ferritin, and creatinine showed differing trends.

Conclusions: Longer hospital stays and higher mortality was observed in exposed cohort than unexposed.

References

1. Cross G, Ho JSY, Zacharias W, Jeyasekharan AD, Marazzi I. Emergency drug use in a pandemic: Harsh lessons from COVID-19. Cell. 2021 Oct 28;184(22):5497-5500. DOI: https://doi.org/10.1016/j.cell.2021.09.025 PMid:34587491 PMCid:PMC8452505

2. Dabholkar N, Gorantla S, Dubey SK, Alexander A, Taliyan R, Singhvi G. Repurposing methylene blue in the management of COVID-19: Mechanistic aspects and clinical investigations. Biomed Pharmacother. 2021 Oct;142:112023. DOI: https://doi.org/10.1016/j.biopha.2021.112023 PMid:34399199 PMCid:PMC8352658

3. Cusinato J, Cau Y, Calvani AM, Mori M. Repurposing drugs for the management of COVID-19. Expert Opin Ther Pat. 2021 Apr;31(4):295-307. DOI: https://doi.org/10.1080/13543776.2021.1861248 PMid:33283567

4. do Nascimento TS, Pereira ROL, de Mello HLD, Costa J. Methemoglobinemia: from diagnosis to treatment. Rev Bras Anestesiol. 2008;58(6):651-664. DOI: https://doi.org/10.1590/S0034-70942008000600011 PMid:19082413

5. Ginimuge PR, Jyothi SD. Methylene Blue: Revisited. J Anaesthesiol Clin Pharmacol. 2010;26(4):517-520. PMid:21547182 PMCid:PMC3087269

6. Lu G, Nagbanshi M, Goldau N, Mendes Jorge M, Meissner P, Jahn A, et al. Efficacy and safety of methylene blue in the treatment of malaria: a systematic review. BMC Med. 2018 Apr 25;16(1):59. DOI: https://doi.org/10.1186/s12916-018-1045-3 PMid:29690878 PMCid:PMC5979000

7. Haouzi P, Gueguinou M, Sonobe T, Judenherc-Haouzi A, Tubbs N, Trebak M, et al. Revisiting the physiological effects of methylene blue as a treatment of cyanide intoxication. Clin Toxicol (Phila). 2018 Sep;56(9):828-840. DOI: https://doi.org/10.1080/15563650.2018.1429615 PMid:29451035 PMCid:PMC6086742

8. Li Z, Lang Y, Sakamuru S, Samrat S, Trudeau N, Kuo L, et al. Methylene blue is a potent and broad-spectrum inhibitor against Zika virus in vitro and in vivo. Emerg Microbes Infect. 9(1):2404-2416. DOI: https://doi.org/10.1080/22221751.2020.1838954 PMid:33078696 PMCid:PMC7646565

9. Mahale N, Godavarthy P, Marreddy S, Gokhale SD, Funde P, Rajhans PA, et al. Intravenous Methylene Blue as a Rescue Therapy in the Management of Refractory Hypoxia in COVID-19 ARDS Patients: A Case Series. Indian J Crit Care Med. 2021 Aug;25(8):934-938. DOI: https://doi.org/10.5005/jp-journals-10071-23905 PMid:34733037 PMCid:PMC8559741

10. Paciullo CA, McMahon Horner D, Hatton KW, Flynn JD. Methylene blue for the treatment of septic shock. Pharmacotherapy. 2010 Jul;30(7):702-715. DOI: https://doi.org/10.1592/phco.30.7.702 PMid:20575634

11. Abd El Megid AGI, El Shabrawy M, Abdalla AAEHM. Correlation between chest CT severity scoring system with oxygen saturation and laboratory inflammatory markers in adult patients with COVID-19 infection. Egypt J Radiol Nucl Med. 2022;53(1):72. DOI: https://doi.org/10.1186/s43055-022-00747-7 PMCid:PMC8927748

12. Akshay B, Krishna AB, Karthik P, Srujana PV. Role of HRCT in Assessing Requirement of Oxygen for COVID-19 Patients: A Retrospective Study from Amalapuram, Andhra Pradesh, India. International Journal of Anatomy, Radiology and Surgery. 2022;11(3):RO16-RO19. DOI: https://doi.org/10.7860/IJARS/2022/53343.2793

13. Mejía F, Medina C, Cornejo E, Morello E, Vásquez S, Alave J, et al. Oxygen saturation as a predictor of mortality in hospitalized adult patients with COVID-19 in a public hospital in Lima, Peru. PLoS One. 2020;15(12):e0244171. DOI: https://doi.org/10.1371/journal.pone.0244171 PMid:33370364 PMCid:PMC7769479

14. Windradi C, Asmarawati TP, Rosyid AN, Marfiani E, Mahdi BA, Martani OS, et al. Hemodynamic, Oxygenation and Lymphocyte Parameters Predict COVID-19 Mortality. Pathophysiology. 2023 Sep;30(3):314-326. DOI: https://doi.org/10.3390/pathophysiology30030025 PMid:37606387 PMCid:PMC10443272

15. Scigliano G, Scigliano GA. Methylene blue in covid-19. Med Hypotheses. 2021 Jan;146:110455. DOI: https://doi.org/10.1016/j.mehy.2020.110455 PMid:33341032 PMCid:PMC7728423

16. Kwok ESH, Howes D. Use of methylene blue in sepsis: a systematic review. J Intensive Care Med. 2006;21(6):359-363. DOI: https://doi.org/10.1177/0885066606290671 PMid:17095500

17. Memis D, Karamanlioglu B, Yuksel M, Gemlik I, Pamukcu Z. The influence of methylene blue infusion on cytokine levels during severe sepsis. Anaesth Intensive Care. 2002 Dec;30(6):755-762. DOI: https://doi.org/10.1177/0310057X0203000606 PMid:12500513

18. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020 Apr;18(4):844-847. DOI: https://doi.org/10.1111/jth.14768 PMid:32073213 PMCID: PMC7166509

19. Garbin JRT, Leite FMC, dos Santos APB, Dell'Antonio LS, Dell'Antonio CS da S, Lopes-Júnior LC. Factors associated with prolonged hospitalizations for COVID-19 during the first three waves of the pandemic: Evidence from a Southeastern State of Brazil. PLoS One. 2025 Sep 9;20(9):e0332128. DOI: https://doi.org/10.1371/journal.pone.0332128 PMid:40924718 PMCid:PMC12419605

20. Barda B, Di Mari B, Soldini E, Di Bartolomeo C, Bissig M, Baserga A, et al. Evaluation of the Efficacy of Methylene Blue Administration in SARS-CoV-2-Affected Patients: A Proof-of-Concept Phase 2, Randomized, Placebo-Controlled, Single-Blind Clinical Trial. Scientia Pharmaceutica. 2024 Dec;92(4):56. DOI: https://doi.org/10.3390/scipharm92040056

21. Sanei ZS, Shahrahmani F, Khaleghi Manesh B, Hamidi-Alamdari D, Mehrad-Majd H, Mavaji Darban B, et al. Methylene blue for COVID-19 ARDS: insights from a randomized Clinical Trial. Naunyn Schmiedebergs Arch Pharmacol. 2025 Feb;398(2):1915-1924. DOI: https://doi.org/10.1007/s00210-024-03371-6 PMid:39207597

22. Ghodke BA, Ghodke A, Mahadik V, Thorat P. Methylene blue treatment for moderate-to-severe cases of acute respiratory syndrome due to COVID-19 infection: clinical outcomes-a prospective study. MGM Journal of Medical Sciences. 2022 Jan;9(1):25-32. DOI: https://doi.org/10.4103/mgmj.mgmj_18_22

23. Liu F, Li L, Xu M, Wu J, Luo D, Zhu Y, et al. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19. J Clin Virol. 2020 Jun;127:104370. DOI: https://doi.org/10.1016/j.jcv.2020.104370 PMid:32344321 PMCid:PMC7194648

24. Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers D a. MPJ, Kant KM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020 Jul;191:145-147. DOI: https://doi.org/10.1016/j.thromres.2020.04.013 PMid:32291094 PMCID: PMC7146714

25. Pushpakom S, Iorio F, Eyers PA, Escott KJ, Hopper S, Wells A, et al. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov. 2019 Jan;18(1):41-58. DOI: https://doi.org/10.1038/nrd.2018.168 PMid:30310233